SPRIM Global Investments

SPRIM Global Investments is a privately held investment firm founded in 2008 that backs clinical-stage life sciences companies and pharmaceutical research and development services. Its portfolio spans biotechnology, medtech, therapeutics, medical devices, digital health, and drug and device development infrastructure. The firm operates from offices in New York and Singapore, with activity across the Americas, Asia-Pacific and Europe.

The firm runs two distinct capital strategies. Direct Equity Investments take stakes in portfolio companies from Series A through growth stage. Alongside this, SPRIM offers Non-Dilutive Credit - financing structured around clinical milestones, giving companies a capital option that does not dilute existing shareholders. This combination allows the firm to support a company through multiple points of its development path rather than at a single financing event.

Investment is paired with operating support: clinical trial execution, regulatory strategy, partnership development and global market access, drawing on an international network. Technical domains of focus include clinical trial execution, regulatory strategy, digital health, medical device development, drug development and life sciences R&D more broadly.

The stated orientation is toward founders advancing health innovations toward clinical validation and broader patient access - a dual emphasis on evidentiary progress and commercial reach that shapes how the firm engages with portfolio companies after investment.